Current developments in pediatric systemic sclerosis

被引:2
|
作者
Foeldvari I. [1 ]
机构
[1] Hamburger Zentrum für Kinder- und Jugendrheumatologie, Kompetenz-Zentrum für Sklerodermie und Autoimmune Uveitis im Kindesalter, Am Klinikum Eilbek, Hamburg D-22081
关键词
Systemic Sclerosis; Organ Involvement; Calcinosis; Mixed Connective Tissue Disease; Skin Score;
D O I
10.1007/s11926-009-0014-4
中图分类号
学科分类号
摘要
Juvenile systemic sclerosis is an orphan disease with an incidence of around 0.05 per 100,000 children. The mean age of onset is approximately 8 years, and 90% of pediatric patients have a diffuse subset. The organ involvement of pediatric patients differs from adult patients. Survival rates are significantly better in pediatric patients than in adult patients. Most patients who die in the first 5 years of the disease have a diffuse subset. Interestingly, the disease subset shifts when pediatric patients are reviewed in adult cohorts of systemic sclerosis patients, in which only around 40% of patients have diffuse subset. The pediatric-onset patients still have a low prevalence of anticentromere antibodies. There is a larger group of patients with overlap features in juvenile systemic sclerosis than in adult cohorts. There are also noticeable differences in organ involvement. © 2009 Current Medicine Group, LLC.
引用
收藏
页码:97 / 102
页数:5
相关论文
共 50 条
  • [31] Systemic sclerosis and the heart: current diagnosis and management
    Desai, Chintan S.
    Lee, Daniel C.
    Shah, Sanjiv J.
    CURRENT OPINION IN RHEUMATOLOGY, 2011, 23 (06) : 545 - 554
  • [32] Current management of the gastrointestinal complications of systemic sclerosis
    Emmanuel, Anton
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2016, 13 (08) : 461 - 472
  • [33] CURRENT APPROACH TO DIGITAL ULCERS IN SYSTEMIC SCLEROSIS
    Lambova, S.
    Batalov, A.
    Dobrev, H.
    Sapundzhiev, L.
    Mueller-Ladner, U.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (02) : S79 - S79
  • [34] Current treatment options in systemic sclerosis (scleroderma)
    Stummvoll, GH
    ACTA MEDICA AUSTRIACA, 2002, 29 (01) : 14 - 19
  • [35] The microbiome and systemic sclerosis: A review of current evidence
    Tan, Tze Chin
    Noviani, Maria
    Leung, Ying Ying
    Low, Andrea Hsiu Ling
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2021, 35 (03):
  • [36] THE SPECTRUM OF SYSTEMIC-SCLEROSIS - CURRENT CONCEPTS
    HOCHBERG, MC
    HOSPITAL PRACTICE, 1981, 16 (03): : 61 - &
  • [37] Current developments in gene therapy for amyotrophic lateral sclerosis
    Scarrott, Joseph M.
    Herranz-Martin, Saul
    Alrafiah, Aziza R.
    Shaw, Pamela J.
    Azzouz, Mimoun
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (07) : 935 - 947
  • [38] CURRENT THERAPY OF SYSTEMIC-SCLEROSIS (SCLERODERMA)
    MULLERLADNER, U
    BENNING, K
    LANG, B
    CLINICAL INVESTIGATOR, 1993, 71 (04): : 257 - 263
  • [39] Systemic treatment of vitiligo. Balance and current developments
    Meurer, M.
    Ceric-Dehdari, P.
    HAUTARZT, 2017, 68 (11): : 876 - 884
  • [40] Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma
    Torok, Kathryn S.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2021, 47 (04) : 757 - 780